Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry

• Hoofdauteurs: Celeste M. Boesjes (Auteur), Liana F. van der Gang (Auteur), Nicolaas P.A. Zuithoff (Auteur), Daphne S. Bakker (Auteur), Lotte S. Spekhorst (Auteur), Inge Haeck (Auteur), Marijke Kamsteeg (Auteur), Marlies de Graaf (Auteur), Marjolein S. de Bruin-Weller (Auteur)
• Formaat: Boek
• Gepubliceerd in: Medical Journals Sweden, 2023-02-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Clinical trials showed that upadacitinib, a selective Janus kinase-1 inhibitor, is effective for treatment of moderate-to-severe atopic dermatitis. However, daily practice studies are limited. This multicentre prospective study evaluated the effectiveness of 16 weeks of upadacitinib treatment for mo...